Cargando…

Low-level whole-brain radiation enhances theranostic potential of single-domain antibody fragments for human epidermal growth factor receptor type 2 (HER2)-positive brain metastases

BACKGROUND: Single-domain antibody fragments (aka V(H)H, ~ 13 kDa) are promising delivery systems for brain tumor theranostics; however, achieving efficient delivery of V(H)H to intracranial lesions remains challenging due to the tumor–brain barrier. Here, we evaluate low-dose whole-brain irradiatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Procissi, Daniele, Jannetti, Stephen A, Zannikou, Markella, Zhou, Zhengyuan, McDougald, Darryl, Kanojia, Deepak, Zhang, Hui, Burdett, Kirsten, Vaidyanathan, Ganesan, Zalutsky, Michael R, Balyasnikova, Irina V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476215/ https://www.ncbi.nlm.nih.gov/pubmed/36128586 http://dx.doi.org/10.1093/noajnl/vdac135

Ejemplares similares

Evaluation of an (131)I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers
por: Feng, Yutian, et al.
Publicado: (2022)

Bi-Specific Killer Cell Engager Enhances NK Cell Activity against Interleukin-13 Receptor Alpha-2 Positive Gliomas
por: Pawlowski, Kristen D., et al.
Publicado: (2023)

MODL-12. DEVELOPMENT OF A NOVEL IMMUNOCOMPETENT MOUSE MODEL FOR DIFFUSE INTRINSIC PONTINE GLIOMA
por: Seblani, Maggie, et al.
Publicado: (2020)

Protein Tyrosine Phosphatase-1B Inhibition Disrupts IL13Rα2-Promoted Invasion and Metastasis in Cancer Cells
por: Bartolomé, Rubén A., et al.
Publicado: (2020)

Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies
por: Laux, I, et al.
Publicado: (2006)

A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumors
por: Kim, Julius W., et al.
Publicado: (2015)

Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies
por: Diaz Miqueli, A, et al.
Publicado: (2009)

Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer
por: Cordero, Alex, et al.
Publicado: (2021)

Gold Nanostars: A Novel Platform for Developing (211)At-Labeled Agents for Targeted Alpha-Particle Therapy
por: Liu, Yang, et al.
Publicado: (2021)

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
por: Khelwatty, Said A, et al.
Publicado: (2015)

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
por: Evans, A H, et al.
Publicado: (2010)

Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma
por: Ramamoorthi, Ganesan, et al.
Publicado: (2022)

HER2 expression as a potential marker for response to therapy targeted to the EGFR
por: Emlet, D R, et al.
Publicado: (2006)

Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma
por: De Silva, Nadeera, et al.
Publicado: (2015)

HER2 expression patterns in paired primary and metastatic endometrial cancer lesions
por: Halle, Mari Kyllesø, et al.
Publicado: (2018)

Observations on the Effects of Residualization and Dehalogenation on the Utility of N-Succinimidyl Ester Acylation Agents for Radioiodination of the Internalizing Antibody Trastuzumab
por: Chitneni, Satish K., et al.
Publicado: (2019)

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
por: Jannetti, Stephen A., et al.
Publicado: (2020)

Targeted radiotherapy of brain tumours
por: Zalutsky, M R
Publicado: (2004)

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
por: Tural, D, et al.
Publicado: (2014)

A Plasmonic Gold Nanostar Theranostic Probe for In Vivo Tumor Imaging and Photothermal Therapy
por: Liu, Yang, et al.
Publicado: (2015)

Syphilis of the Brain
Publicado: (1882)

Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas
por: Berta, G N, et al.
Publicado: (2005)

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma
por: Kawaguchi, Y, et al.
Publicado: (2007)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
por: Peiró, G, et al.
Publicado: (2014)

Poziotinib Inhibits HER2-Mutant–Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer
por: Kalra, Rashi, et al.
Publicado: (2022)

WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models
por: Conage-Pough, Jason E, et al.
Publicado: (2023)

HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma
por: Liu, Y J, et al.
Publicado: (2014)

Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)
por: Feilchenfeldt, J, et al.
Publicado: (2015)

Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)
por: Feilchenfeldt, J, et al.
Publicado: (2015)

Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer
por: McGranahan, Tresa M., et al.
Publicado: (2022)

Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data
por: Anwar, Munawar, et al.
Publicado: (2021)

FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis
por: Cordero, Alex, et al.
Publicado: (2019)

Human responses against HER-2-positive cancer cells in human immune system-engrafted mice
por: De Giovanni, C, et al.
Publicado: (2012)

Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
por: Duro-Sánchez, Santiago, et al.
Publicado: (2022)

Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct
por: Roth, A, et al.
Publicado: (2005)

Theranostic application of miR-429 in HER2+ breast cancer
por: Cava, Claudia, et al.
Publicado: (2020)

Mechanistic Modeling of Central Nervous System Pharmacokinetics and Target Engagement of HER2 Tyrosine Kinase Inhibitors to Inform Treatment of Breast Cancer Brain Metastases
por: Li, Jing, et al.
Publicado: (2022)

Molecular aging of the brain, neuroplasticity, and vulnerability to depression and other brain-related disorders
por: Sibille, Etienne
Publicado: (2013)

d-Amino Acid Peptide Residualizing Agents for Protein Radioiodination: Effect of Aspartate for Glutamate Substitution
por: Pruszynski, Marek, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vh32l9vd39a8ud077vt2r3ij20